Treatment of Treatment-Resistant Psychosis

Initial Assessment and Treatment

The American Psychiatric Association recommends transitioning to clozapine monotherapy immediately if clozapine has not been tried, as it is the only FDA-approved medication for treatment-resistant schizophrenia 1, 3, 4, 5
An adequate trial of clozapine requires therapeutic blood levels ≥350 ng/mL maintained for at least 3 months, or a minimum dose of 500 mg/day if blood monitoring is unavailable 2
The World Federation of Societies of Biological Psychiatry and NICE establish clozapine as the definitive treatment after failure of two adequate non-clozapine antipsychotic trials 3, 4, 5

The American Psychiatric Association recommends augmenting clozapine with aripiprazole as the preferred strategy for clozapine-resistant cases 6
NICE guidelines allow adding another antipsychotic to augment clozapine when monotherapy proves ineffective, recommending selection of an agent that doesn't compound clozapine's side effects 3, 4
Aripiprazole may reduce clozapine dose requirements, treatment side effects, and residual symptoms 1

The American Psychiatric Association suggests that non-clozapine antipsychotic polypharmacy may be considered only after clozapine intolerance is confirmed 1, 6
Critical management points for continuing polypharmacy include documenting baseline symptoms, scheduling follow-up, and attempting gradual reduction back to monotherapy if stable improvement is achieved 1

The American Psychiatric Association recommends documenting specific target symptoms and severity at baseline, reassessing at 4-8 weeks, and monitoring for additive side effects 1, 2
Regular monitoring for clozapine includes ANC monitoring, orthostatic hypotension, myocarditis/cardiomyopathy, and seizure precautions 3, 4